Silence Therapeutics PLC(US:SLN)2025-11-06 12:38Financial Performance - Revenue for Q3 2025 was $159,000, compared to $1.5 million in Q3 2024[11] - Gross profit for Q3 2025 was $95,000, compared to a gross loss of $2.1 million in Q3 2024[11] - Net loss for Q3 2025 was $21.0 million, down from $35.5 million in Q3 2024, largely due to foreign currency loss[4] - Research and development expenses for Q3 2025 were $20.5 million, slightly up from $20.2 million in Q3 2024[4] - General and administrative expenses decreased to $5.8 million in Q3 2025 from $7.7 million in Q3 2024, a reduction of $1.9 million[4] Cash Position - Cash and cash equivalents, and short-term investments totaled $102.2 million as of September 30, 2025, expected to fund operations into 2028[4] Clinical Development - Completed enrollment in the SANRECO Phase 2 study of divesiran for polycythemia vera (PV) with 48 patients enrolled[4] - Anticipated topline results from the SANRECO Phase 2 study are expected in Q3 2026[4] - The company aims to advance additional candidates from its mRNAi GOLD™ platform, indicating potential for future growth[2] Share Information - The weighted average shares outstanding for Q3 2025 were 141,701,848[11]